This trial is testing a new antibody to treat DLBCL, a type of blood cancer. The trial will compare the new treatment to the standard of care to see if it is more effective with fewer side effects.
1 Primary · 9 Secondary · Reporting Duration: From randomization until the date of death from any cause (up to 62 months)
880 Total Participants · 2 Treatment Groups
Primary Treatment: Tafasitamab · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: